CMEL
THE UNIVERSITY OF HONG KONG
CENTRE FOR MEDICAL ETHICS AND LAW

"Governing the Real World Application of Medical AI" Conference 15-16 Nov 2024

Date:	Friday, 15 Nov 2024 (**by invitation only**) Saturday, 16 Nov 2024 (prior registration is required; open to other interested parties, particularly welcome academics, practitioners and students from the legal and healthcare fields) The sessions on Day 1 (15 Nov) are for presentations and deliberations by invited delegates only. The session on Day 2 (16 Nov) is open for general registration and will begin with a summary of the discussions on Day 1.
Mode:	Friday, 15 Nov 2024: in person only Saturday, 16 Nov 2024: in person or Zoom
Venue:	11/F, Cheng Yu Tung Tower, Centennial Campus, The University of Hong Kong, Hong Kong
Abstracts and biographies:	Please refer to the last section of this document.
Organiser:	Centre for Medical Ethics and Law (CMEL), HKU
Supporting Organisations:	The Hong Kong Academy of Medicine Medical Ethics and Humanities Unit (MEHU), HKU

This conference aims at exploring how best to develop an appropriate governance framework in Hong Kong in relation to the adoption of Artificial Intelligence (AI) technologies in healthcare.

There will be sharing on the regulatory context of AI in healthcare in Hong Kong and other jurisdictions, such as the European Union (EU), Mainland China, the UK, Canada, the US and the Middle East.

This conference will examine the matter from legal and ethical perspectives and consider developments in other jurisdictions, in particular, the newly enacted regimes of the EU AI Act and the European Health Data Space, as well as their relevance to Hong Kong.

It is hoped that the exchange and sharing of experience at the conference will shed light on the measures (e.g. guidelines, regulation, legislation) that may serve as a helpful reference for developing measures in meeting the multitude of challenges arising from AI in healthcare in Hong Kong.

Governing the Real World Application of Medical AI

Fri - Sat 15 - 16 Nov 2024

Fri 15 Nov (by invitation only)
Sat 16 Nov | 9:00 am – 12:35 pm HKT (open to public)
(11/F, Cheng Yu Tung Tower, HKU & Zoom)

- Legal developments in healthcare artificial intelligence (AI) regulation in EU & other jurisdictions and the regulatory context in Hong Kong
- Ethical challenges in healthcare AI

Programme & Registration

Enquiry: cmel@hku.hk

Organiser:

CMEL THE UNIVERSITY OF HONG KONG CENTRE FOR MEDICAL ETHICS AND LAW

HKU LAW

Supporting Organisations:

HONG KONG ACADEMY OF MEDICINE 香港醫學專科學院

HKU Med School of Clinical Medicine Medical Ethics & Humanities Unit 香港大學醫學倫理及人文學部

The Programme –
Day 1
Sessions 1 and 2 (by invitation only)

15 Nov 2024, Friday
9:00 – 13:15 (Hong Kong Time)
11/F, Cheng Yu Tung Tower, Centennial Campus, HKU

9:00 – 9:05	**Welcome and introduction** **Prof Gilberto Leung** Co-Director, Centre for Medical Ethics and Law Tsang Wing-Hing Professor in Clinical Neuroscience and Clinical Professor, LKS Faculty of Medicine The University of Hong Kong & President, Hong Kong Academy of Medicine Hong Kong, China
9:05 – 9:10	**Speech by Guest of Honour** **Dr LEE Ha Yun, Libby, JP** Under Secretary for Health, Health Bureau, Government of the Hong Kong Special Administrative Region (HKSAR), China
9:10 – 9:15	**Photo session**
Session 1: Governance of Healthcare AI in the EU and the UK **Chair:** **Prof Eric C. Ip** Co-Director of the Centre for Medical Ethics and Law & Professor of the Faculty of Law The University of Hong Kong, Hong Kong, China	
9:15 – 9:45	**Shaping tomorrow's healthcare: The European Union AI Act and its implications in medicine [Abstract at the end of programme]** **Prof Vera Raposo** Associate Professor of Law and Technology, NOVA School of Law, Portugal
9:45 – 10:15	**The European Health Data Space: Realistic ambitions for health research and innovation? [Abstract at the end of programme]**

	Dr Colin Mitchell Head of Humanities, PHG Foundation, University of Cambridge, UK
10:15 – 10:35	**The UK approach to regulating AI: Innovation first, safety second? [Abstract at the end of programme]** **Prof Oliver Quick** Professor of Health Law and Policy, University of Bristol Law School, UK
10:35 – 10:45	**Intermission**
Session 2: Governance of Medical AI: the Local Situation **Chair:** Prof Gilberto Leung Co-Director, Centre for Medical Ethics and Law Tsang Wing-Hing Professor in Clinical Neuroscience and Clinical Professor, LKS Faculty of Medicine The University of Hong Kong & President, Hong Kong Academy of Medicine Hong Kong, China	
10:45 – 11:05	**Opportunities and challenges of applying AI for medical applications [Abstract at the end of programme]** **Mr Donald Mak** Deputy Commissioner for Digital Policy (Data Governance) Digital Policy Office, Innovation, Technology and Industry Bureau, Government of the HKSAR, China
11:05 – 11:35	**AI-enabled assisted reproduction: regulatory and ethical issues in Mainland China and Macau & Hong Kong perspective on AI-enabled assisted reproduction [Abstract at the end of programme]** **Prof Stephen Li Du** Associate Professor, Faculty of Law, University of Macau, Macau, China **Prof Calvin Ho** Research Fellow, Centre for Medical Ethics and Law, The University of Hong Kong, Hong Kong, China Associate Professor, Monash Law School, Monash University, Australia

11:35 – 11:55	**Ethics governance on medical AI research and development in Shenzhen, China [Abstract at the end of programme]** **Dr JI Ping** Vice Director, Clinical Research Institute, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, China
11:55 – 12:15	**AI for medical innovation – from medical device's perspective [Abstract at the end of programme]** **Ir LAM Kam Chun, Tommy** Senior Electronics Engineer (Medical Device) Medical Device Division, Department of Health Government of the HKSAR, China
12:15 – 13:15	**Roundtable Discussion** **Prof Vera Raposo, Dr Colin Mitchell, Prof Oliver Quick, Mr Donald Mak, Prof Stephen Li Du, Prof Calvin Ho, Dr JI Ping, Ir LAM Kam Chun, Tommy** Chairs: Prof Gilberto Leung and Prof Eric C. Ip
13:15 – 14:30	**Lunch (for invitees only)**

The Programme –
Day 1
Sessions 3 & 4 (by invitation only)

15 Nov 2024, Friday
14:30 – 17:45 (Hong Kong Time)
11/F, Cheng Yu Tung Tower, Centennial Campus, HKU

Session 3: More on AI Governance in the EU and Canada **Chair:** Dr Pete Mills Director, PHG Foundation, University of Cambridge, UK	
14:30 – 14:50	**Ensuring a trustworthy use of medical AI through regulation - the European perspective [Abstract at the end of programme]** **Prof Tom Goffin** Associate Professor of Health Law, Metamedica, Ghent University, Belgium
14:50 – 15:10	**Navigating the EU AI Act and the Medical Device Regulation (MDR): Implications for regulated digital medical products [Abstract at the end of programme]** **Prof Timo Minssen** Professor of Law Managing Director and Founder of Center for Advanced Studies and the Collaborative Research Programme in Biomedical Innovation Law (CeBIL) University of Copenhagen, Denmark
15:10 – 15:30	**From code to care: Regulating AI in Canadian healthcare [Abstract at the end of programme]** **Yuan Y. Stevens** Academic Associate, Centre of Genomics and Policy, McGill University, Canada
15:30 – 16:00	**Q&A** **Prof Tom Goffin, Prof Timo Minssen, Yuan Y. Stevens** Chair: Dr Pete Mills

16:00 – 16:15	**Intermission**
Session 4: Regulating AI in the US and Beyond **Chair:** Dr Colin Mitchell Head of Humanities, PHG Foundation, University of Cambridge, UK	
16:15 – 16:35	**Regulating AI/ML in U.S. healthcare: challenges, Opportunities, and FDA's Evolving Framework [Abstract at the end of programme]** **Prof Sara Gerke** Associate Professor of Law and Richard W. & Marie L. Corman Scholar, College of Law, University of Illinois Urbana-Champaign, US
16:35 – 16:55	**Managing failure: How should we track and govern problems arising from medical AI/ML devices? [Abstract at the end of programme]** **Prof Boris Babic** Associate Professor, HKU Musketeers Foundation Institute of Data Science and Department of Philosophy Associate Professor (by courtesy), Faculty of Law The University of Hong Kong, Hong Kong, China
16:55 – 17:15	**A GCC approach towards regulating the lifecycle of healthcare AI [Abstract at the end of programme]** **Dr Barry Solaiman** Assistant Professor of Law, College of Law, Hamad Bin Khalifa University, Qatar, Doha
17:15 – 17:45	**Q&A** **Prof Sara Gerke, Prof Boris Babic and Dr Barry Solaiman** Chair: Dr Colin Mitchell
After session 4 ends	**Dinner (for invitees only)**

The Programme –
Day 2
Session 5

16 Nov 2024, Saturday
9:00 – 12:35 (Hong Kong Time)
11/F, Cheng Yu Tung Tower, Centennial Campus, HKU or Zoom

Session 5: Legal and Ethical Considerations of AI Governance in Healthcare	
9:00 – 9:10	**Introduction** **Prof Eric C. Ip** Co-Director, Centre for Medical Ethics and Law Professor, Faculty of Law The University of Hong Kong, Hong Kong, China
Chair before intermission: Dr Pete Mills Director, PHG Foundation, University of Cambridge, UK	
9:10 – 9:40	**Summary of discussion on Day 1** **Prof Gilberto Leung** Co-Director, Centre for Medical Ethics and Law Tsang Wing-Hing Professor in Clinical Neuroscience and Clinical Professor, LKS Faculty of Medicine The University of Hong Kong & President, Hong Kong Academy of Medicine Hong Kong, China **Prof Calvin Ho** Research Fellow, Centre for Medical Ethics and Law, The University of Hong Kong, Hong Kong, China Associate Professor, Monash Law School**,** Monash University, Australia
9:40 – 10:00	**Role of AI in medical and public health policymaking [Abstract at the end of programme]** **Prof Brian Wong** Assistant Professor, Department of Philosophy, The University of Hong Kong, Hong Kong, China

10:00 – 10:20	**Medical AI assistants vs. Medical AI dictators [Abstract at the end of programme]** **Prof Herman Cappelen** Chair Professor, Department of Philosophy Director of AI & Humanity Lab and Co-director of ConceptLab The University of Hong Kong, Hong Kong, China
10:20 – 10:40	**Ethical considerations for the trustworthy use of medical AI [Abstract at the end of programme]** **Tanya Brigden** Senior Policy Analyst, PHG Foundation, University of Cambridge, UK
10:40 – 10:55	**Intermission**
Chair after intermission: Dr Colin Mitchell Head of Humanities, PHG Foundation, University of Cambridge, UK	
10:55 – 11:15	**The AI as expert: some epistemological and moral considerations [Abstract at the end of programme]** **Dr Pete Mills** Director, PHG Foundation, University of Cambridge, UK
11:15 – 11:35	**Emerging ethical challenges in medical AI: persuasion, manipulation and consent [Abstract at the end of programme]** **Prof Rachel Sterken** Associate Professor, Department of Philosophy Co-director of ConceptLab The University of Hong Kong, Hong Kong, China
11:35 – 12:35	**Roundtable Discussion** **Prof Gilberto Leung, Prof Calvin Ho, Prof Herman Cappelen, Tanya Brigden, Dr Pete Mills, Prof Rachel Sterken** Chair: Dr Colin Mitchell
After session 5 ends	**Lunch (for invitees only)**

Guest of Honour

Speaker:
Dr Libby Lee
Undersecretary
Health Bureau, The Government of the Hong Kong Special Administrative Region

FANZCA, FHKCA, FHKAM (Anaes), Dip Pain Mgt (HKCA), MPH (HK), FFPH, FHKCHSE, FACHSM, FRACMA

Biography:

Dr. LEE is the Undersecretary of Health Bureau, the Hong Kong Special Administrative Region since July 2022. She was the Director of the Strategy and Planning Division at the Hospital Authority administration before the current position. The Hospital Authority provides public healthcare services to the 7 million Hong Kong population through 27,000 beds in 43 public hospitals. The scope of her works includes strategy, service, capital and annual planning for the whole Hospital Authority. The current projects include the Hong Kong Children's Hospital, Queen Mary Hospital, United Christian Hospital, Kwong Wah Hospital, and the Hospital at Kai Tak etc.

She is trained as anaesthesiologist in Queen Mary Hospital focusing on liver transplantation, pain management, electronic anaesthetic record system and simulation training. In 2008, she started her career in administration, first in Patient Safety and Risk Management as the Head of the Patient Safety and Risk Management Department in the Hospital Authority administration. The Department identifies clinical risks through incident management and the annual risk registration exercises, through which corporate strategies and risk reduction programmes are formulated, and quality improvement programmes in individual hospitals and clusters are facilitated and monitored. She then works in the Division of Strategy and Planning for public healthcare services development since 2011. In 2015, she also takes up the position of Deputizing Hospital Chief Executive of the Buddhist Hospital, overseeing the operations of the hospital as well as its refurbishment works.

Speaker:
Prof Gilberto Leung
Co-Director, Centre for Medical Ethics and Law
Tsang Wing-Hing Professor in Clinical Neuroscience and Clinical Professor, LKS Faculty of Medicine
The University of Hong Kong
&
President, Hong Kong Academy of Medicine
Hong Kong, China

Biography:

Professor Gilberto Leung is a neurosurgeon, Clinical Professor, and holder of the endowed Tsang Wing-Hing Professorship in Clinical Neuroscience at the University of Hong Kong (HKU). He graduated from the University of London with MBBS in 1992. During postgraduate training, he was awarded the Hallett Gold Medal and the J. Douglas Miller Medal in Neurosurgery by the Royal College of Surgeons of England and that of Edinburgh, respectively. He obtained his MS, PhD and MD from HKU; LLB from the University of London; and LLM in Medical Law and Ethics with Distinction from the University of Edinburgh. He is currently President of the Hong Kong Academy of Medicine, Co-Director of the Centre for Medical Ethics and Law at HKU, Associate Dean of the HKU medical faculty, and Honorary Consultant Neurosurgeon at Queen Mary Hospital.

Speaker:
Prof Eric C. Ip
Co-Director, Centre for Medical Ethics and Law
Professor, Faculty of Law
The University of Hong Kong, Hong Kong, China

Biography:

Eric is a public health bioethicist and Co-Director of the Centre for Medical Ethics and Law at the University of Hong Kong (HKU), where he is Professor of Law. He holds a Doctor of Philosophy in Socio-Legal Studies from the Faculty of Law, University of Oxford, and a Master of Bioethics from the Faculty of Medicine and Health, The University of Sydney, among other academic degrees. He has been awarded the Outstanding Young Researcher Award, University Research Output Prize, and Faculty Outstanding Teaching Award by HKU, and the Research Excellence Award and Young Researcher Award by The Chinese University of Hong Kong, where he served as Assistant Dean for Undergraduate Studies and Director of the LLB Programme.

Presentation Title: Shaping Tomorrow's Healthcare: The European Union AI Act and Its Implications in Medicine

Speaker:
Prof Vera Raposo
Associate Professor of Law and Technology, NOVA School of Law, Portugal

The European Union AI Act (AIA) represents a key regulatory framework aimed at ensuring the safe and ethical development, deployment, and use of artificial intelligence (AI) across sectors, including healthcare. As AI becomes increasingly integrated into diagnostic tools, treatment planning, and personalized medicine, the regulatory landscape must adapt to address the unique challenges posed by these technologies.

I will examine the risk-based classification system of the AIA, particularly how healthcare AI systems are categorized as high-risk. Specific sections of the AIA related to transparency, explainability, and human oversight will be discussed in the context of healthcare applications, ensuring that AI tools enhance patient care without undermining trust or safety.

Furthermore, the talk will delve into the relationship between the AI Act and the Medical Device Regulation (MDR), analyzing how the two frameworks intersect, especially in the classification, conformity assessment, and post-market surveillance of AI-powered medical devices. By aligning the AI Act with the MDR, the European Union aims to create a coherent regulatory environment that fosters innovation while ensuring that AI systems in healthcare meet high standards of quality, safety, and ethical compliance. It remains to be seen, however, how these two regulations will work together.

This talk will provide critical insights into how the AI Act is shaping the future of healthcare, balancing technological advancement with patient-centric protections.

Biography:

Vera Lúcia Raposo earned her law degree from the Faculty of Law at the University of Coimbra, where she also completed her postgraduate studies in medical law and obtained her master's and doctoral degrees in legal and political sciences. She currently holds the position of Associate Professor of Law and Technology and Vice-Director at Nova School of Law, NOVA University Lisbon.

In the past, she taught at the University of Macau (China), the University of Coimbra (Portugal), and Agostinho Neto University (Angola). She also served as a supervisor for postgraduate studies at the Centre for Medical Ethics and Law at the University of Hong Kong (China) and as a guest lecturer at the School of Law, National Yang Ming Chiao Tung University in Taiwan.

Vera is an active member of the European Association of Health Law and a Governor of the World Association for Medical Law. She serves on the Editorial Board of the European Journal of Health Law and she is actively engaged in peer reviews for some of the most prestigious scientific journals in her field. In 2024, she became a fellow of the prestigious Hastings Centre. Vera is also the author of numerous studies, particularly in the areas of digital law and biomedical law, most of which have been published in indexed journals.

Presentation Title: The European Health Data Space: realistic ambitions for health research and innovation?

Speaker:
Dr Colin Mitchell
Head of Humanities, PHG Foundation, University of Cambridge, UK

Abstract:

The European Health Data Space (EHDS) presents an ambitious and significant step towards a more integrated and streamlined approach to data access for health research and innovation with the potential to accelerate scientific progress, boost collaboration, and facilitate knowledge transfer between different scientific disciplines. However, the scale of the challenges that must be addressed for full and effective implementation cannot be underestimated. Without addressing the many known barriers already facing cross-border research, this may only increase the scale of existing data sharing challenges. In particular, the default that health data must be made available within the EHDS (without consent) combined with potential Member State measures to re-introduce consent may challenge both public trust and confidence in the data space and the quality and utility of the datasets for researchers. There will also be technical challenges such as the challenges of integrating multiple datasets from different sources while preserving data quality and consistency. The success of the EHDS will depend heavily on political will across the EU. For countries outside the EU, it remains to be seen to what extent it may be feasible to take part in the EHDS on the basis of reciprocal arrangements. This presentation will consider these challenges and benefits of the EHDS for researchers and innovators within and outside the EU.

Biography:

Colin is Head of Humanities at the UK based health policy research organisation, the PHG Foundation, which is a linked charity of the University of Cambridge. He leads a team addressing legal, ethical and societal issues that arise with biomedical innovation and new health technologies. This includes challenges associated with genomic data processing, artificial intelligence and the obligations of health and scientific professionals in the contemporary biomedical landscape. Colin has a PhD in health law from the University of Amsterdam, a Masters of Studies in Legal Research from the University of Oxford and a BA in Law from the University of Cambridge.

Presentation Title: The UK approach to regulating AI: Innovation first, safety second?

Speaker:
Prof Oliver Quick, Professor of Health Law and Policy, University of Bristol Law School, UK

Abstract:

In February 2024, the UK Government confirmed its commitment to a "pro innovation" approach to regulating Artificial Intelligence. This non-statutory sector specific model adopts a 'wait and see' position towards managing the risks associated with AI. This light touch approach is in stark contrast to the extensive legislative framework produced by the European Union.

Instead of creating an AI specific super regulator or introducing new legal rules, the UK approach seeks soft compliance with the following cross sectoral principles: safety, security and robustness; appropriate transparency and explainability; fairness; accountability and governance, and contestability and redress.

This talk will examine some key questions about the relationship between innovative technologies and healthcare regulation. How will this UK principles based approach to regulation be delivered? Is this agile regulation or active de-regulation which unduly prioritises digital industrial policy goals? Can current mechanisms ensure sufficient safety and adequate redress for AI related healthcare harm? Finally, is the apparent tension between pro innovation and reluctant regulation ultimately a false dichotomy?

Biography:

Prof Oliver Quick is Professor of Health Law and International Director at the University of Bristol Law School. He teaches UG and PG courses on Medical Law, Health Law and Criminal Law (including a Criminal Law course at HKU SPACE). His research is interdisciplinary and impactful and focuses on professionalism, regulation, safety, and trust in healthcare. His monograph *Regulating Patient Safety: the End of Professional Dominance?* (CUP, 2017) was shortlisted for the St Petersburg International Private Law Prize in 2019. Prof Quick has published widely on the need for candour about healthcare harm, comparative systems for incentivising safer maternity care, the criminalization of medical harm, professional fitness to practise frameworks, and the benefits and harms of digital health technologies. He has been a visiting fellow at the University of Auckland, Boston University, University of British Columbia, NUS and UWA.

Presentation Title: Opportunities and Challenges of Applying AI for Medical Applications

Speaker:
Mr Donald Mak
Deputy Commissioner (Data Governance)
Digital Policy Office
The Government of the Hong Kong Special Administrative Region

Abstract:

AI is an essential driver of new production in the digital era. The rapid advancement of AI technology has opened up exciting new possibilities in the medical field. The presentation will explore the opportunities and challenges of applying AI in healthcare and highlight the proactive efforts of the HKSAR Government to support AI development and adoption in Hong Kong.

AI can revolutionise healthcare by improving diagnostics, personalising treatment plans and enhancing patient outcomes. However, these opportunities come with challenges. The presentation will underline the risks and the importance of various ethical considerations in the adoption of AI. An ethical and trustworthy AI ecosystem is crucial for balancing the benefits and the risks while maintaining public trust in AI. The Government has been adopting an all-round approach to develop the AI ecosystem of Hong Kong on various fronts, and actively applying AI technology to promote the development of smart city and digital government. The presentation will also cover key government initiatives that support AI development and adoption in the healthcare sector.

Biography:

As the Deputy Commissioner (Data Governance), Mr Donald Mak has been actively involved in promoting Government's agenda for innovation, technology adoption and public services improvement. He also played a key role in the implementation of a number of digital government infrastructures (including the government cloud infrastructure, big data analytics platform, shared blockchain platform, consented data exchange gateway) and the formulation and implementation of open data policy.

Mr Mak joined the Government in 1989. Since then he has assumed various important duties including formulation and implementation of facilitation strategy and initiatives for ICT industry development, data centre development, digital inclusion, ICT co-operation with the Mainland and overseas economies as well as the implementation and management of various government ICT systems and services.

Presentation Title: AI-enabled assisted reproduction: regulatory and ethical issues in Mainland China and Macau & Hong Kong perspective on AI-enabled assisted reproduction

Speakers:

Prof Stephen Li Du
Associate Professor, Faculty of Law, University of Macau, Macau, China

Prof Calvin Ho
Research Fellow, Centre for Medical Ethics and Law, The University of Hong Kong, Hong Kong, China
Associate Professor, Monash Law School, Monash University, Australia

Abstract:

In the context of decreasing fertility rates globally, assisted reproduction (AR) technologies, particularly in vitro fertilization (IVF), have played a crucial role in treating human infertility and ensuring reproductive autonomy. More recently, advances in information and communication technologies have introduced digital tools and artificial intelligence (AI) into AR treatments. Although AI holds the potential to enhance the success rate of IVF, the growth of AI-enabled AR and its incorporation into clinical settings are still faced with numerous ethical and legal hurdles. These challenges have not yet been adequately explored. Prof Li Du will explore these issues in the context of Mainland China and Macau in this presentation. Specifically, Prof Du will examine the relevant Mainland Chinese and Macau laws concerning AI-enabled assisted reproductive technology research and usage, identifying key regulatory challenges that may influence the progress of AI-enabled AR research and applications in Mainland China and Macau. Prof Calvin Ho will provide a Hong Kong perspective on AI-enabled assisted reproduction in this presentation.

Biographies:

Prof Li Du is an Associate Professor at the University of Macau, Faculty of Law. Prof Du graduated from Wuhan University, China with dual Bachelor Degrees in both law and clinic medicine in 2005, and received Doctoral Degree in law from the Faculty of Law, University of Alberta, Canada in 2014. His research interests have focused on legal, ethical, and social issues related to cutting-edge biotechnology, e.g., stem cell research and clinical application, genetic testing and gene patents, AI and biomedical research etc.

Prof Calvin Ho is Associate Professor with the Monash Law School, a Research Fellow of the Centre for Medical Ethics and Law (CMEL) at the University of Hong Kong (HKU), a Fellow of PHG Foundation at the University of Cambridge, and a Fellow of the Royal Society for Public Health UK. He co-chairs the Expert Group of the World Health Organization (WHO) on the Ethics of Social Listening and Infodemic Management, and is an Ethics Board member of Médecins Sans Frontières (Doctors Without Borders).

Prior to his current appointment, Calvin was Associate Professor with HKU Faculty of Law, and Co-Director of CMEL, which is jointly run by the Faculty of Law and Faculty of Medicine at HKU. Before this, he was Assistant Professor with the Centre for Biomedical Ethics of the Yong Loo Lin School of Medicine at the National University of Singapore, and also Co-Head of the World Health Organization Collaborating Centre on Bioethics in Singapore. Calvin has practiced law in London and Singapore with Messrs Linklaters Allen & Gledhill, and served as an Assistant Director of the Legal Aid Bureau (Ministry of Law) in Singapore.

Calvin's research is on global health law and ethics, law and ethics in the context of emerging health technologies (with focus on Artificial Intelligence and data analytics), and on medical law and ethics.

Presentation Title: Ethics governance on Medical AI Research and Development in Shenzhen, China

Speaker:
Dr Ji Ping, MD, PhD
Vice Director, Clinical Research Institute, Shenzhen Peking University-Hong Kong University of Science and Technology Medical Center, China

Abstract:

Firstly, this talk introduces the status and performance of health AI in China based on the 2023 health AI index report, which was released by National Big Health Data Institute at Peking University. It then gives an introduction on the current challenges and features associated with Ethical Governance of healthcare AI R&D in Shenzhen. Favorable driving factors for medical AI R&D in Shenzhen identified by all stakeholders included the recent trend of increased governmental funding, supportive governmental policies, wide recognition of the value and high supportive demands from local industry and research institutes. The major challenges include involving multiple regulatory departments, unclear ethical supervision and review path, and lack of capable ethical management resources. Strategies were proposed including to develop specific work guidelines, risk-based grading supervision model, joint governance mechanism of multi-party cooperation, to provide ethical review skills training and accreditation standards services. Only with the implementation of effective governance policies, and a well-established accountability sharing system can Shenzhen achieve its potential to become a fertile field for healthcare AI innovation.

Biography:

Dr Ji Ping began her clinical research career as medical writer in 2007 after obtaining her PhD in Cardiff University, UK. She has rich experience in protocol development and project quality management for Phase I to IV new drug development, national and international investigator–initiated studies. Dr Ji also took the role as Director of Quality Assurance Office in Peking University Human Research Protection Program (PU HRPP). Her primary responsibilities were to oversee clinical research projects implementation and assure high quality operation in Peking University Clinical Research Institute between 2010-2016.

Since July 2016, she moved to Shenzhen for building clinical research oversight and support platforms for education & training, technological support, and policy development. Dr Ji has been appointed as Director for Shenzhen Quality Control Center of Clinical Research by Shenzhen Health Committee. As the core member for Shenzhen Biomedical Ethical Review Board, she has made great efforts to develop ethical governance system in biomedical field. In recent years, she has been involved in ethics governance for medical AI, health data, Science and Technology fields in Shenzhen.

Research Interests:
Quality Management in Clinical Research; Governance over Ethics in Biomedical Research

Presentation Title: AI for medical innovation – from medical device's perspective

Speaker:
Ir LAM Kam Chun, Tommy
Senior Electronics Engineer (Medical Device)
Medical Device Division, Department of Health
The Government of the Hong Kong Special Administrative Region

Abstract:

Artificial Intelligence (AI) is revolutionizing the medical field, with applications spanning medical image analysis, biosignal interpretation, and drug discovery. The Department of Health of the Hong Kong SAR serves as a crucial regulatory authority, ensuring the safety, quality, and performance of AI-driven medical devices. This presentation will explore the integration of AI in healthcare, particularly focusing on potential use of AI on medical devices from a biomedical engineering perspective. It will delve into the unique and emerging challenges associated with adoption and regulation of these technologies. Additionally, the presentation will provide updates on the existing Medical Device Administrative Control System implemented by the Department of Health; and will outline future plans for the local regulatory framework, emphasizing the necessary adaptations to foster innovation while safeguarding public health.

Biography:

Ir Tommy LAM is the Senior Engineer of the Medical Device Division in the Department of Health of the HKSAR Government. He is a corporate member in the Biomedical discipline of the Hong Kong Institution of Engineers and has over 16 years of sound experience in electronics and biomedical engineering, Ir Tommy LAM has previously worked in hospital engineering and innovation and technology at the Electrical and Mechanical Services Department, with a particular focus on artificial intelligence and digitalization projects. He is currently responsible for the implementation of the Medical Device Administrative Control System, with a view to facilitating transition to a long-term statutory regulatory framework for medical devices in Hong Kong.

Presentation Title: Ensuring a trustworthy use of medical AI through regulation - the European perspective

Speaker:
Prof Tom Goffin
Associate Professor of Health Law, Metamedica, Ghent University, Belgium

Abstract:

The trustworthy use of medical AI in Europe hinges on the regulatory frameworks established by the European Union's AI Act, the proposed AI Liability Directive, and the AI Convention of the Council of Europe. The AI Act, a pioneering legislative initiative, classifies AI systems based on risk categories and imposes strict requirements on high-risk systems, including those used in healthcare. It mandates transparency, data governance, and robust human oversight to ensure safety and fairness in AI-driven medical applications. Complementing this, the proposed AI Liability Directive introduces rules on liability for harm caused by AI systems, simplifying legal processes for individuals seeking compensation for damages related to AI technologies. This fosters accountability and strengthens trust in AI-driven healthcare solutions. Additionally, the AI Convention of the Council of Europe reinforces human rights protections in AI, emphasizing the ethical use of AI systems and their compliance with fundamental rights, privacy, and non-discrimination principles. Together, these legislative frameworks ensure a comprehensive approach to regulating medical AI, emphasizing patient safety, data protection, and legal accountability. This presentation gives an overview of these regulatory frameworks and discusses the current pitfalls they have within healthcare.

Biography:

Prof Tom Goffin is a prominent legal scholar and academic known for his expertise in health law, bioethics, and medical AI regulation. Based in Belgium, he serves as an associate professor at Ghent University, where he focuses on the intersection of law, technology, and healthcare. His work often explores the ethical and legal challenges surrounding the use of emerging technologies in medicine, including artificial intelligence (AI), organization of healthcare, and patients' rights. Goffin has contributed significantly to the understanding of how AI can be integrated into healthcare in a trustworthy and legally compliant manner.

In addition to his academic contributions, Goffin plays an active role in advising governmental and international bodies on the legal aspects of healthcare innovation. His research often bridges the gap between theoretical legal analysis and practical regulatory solutions, making him a key figure in shaping the future of health law in Europe. Through his publications, lectures, and consultations, Tom Goffin continues to influence the evolving landscape of medical law, ensuring that technological advancements align with ethical standards legal accountability and healthcare organization.

Presentation Title: Navigating the EU AI Act and the Medical Device Regulation (MDR): Implications for Regulated Digital Medical Products

Speaker:
Prof Timo Minssen
Professor of Law
Managing Director and Founder of Center for Advanced Studies and the Collaborative Research Programme in Biomedical Innovation Law (CeBIL)
University of Copenhagen, Denmark

Abstract:

The newly adopted EU AI Act represents a pivotal milestone that signifies a new era of AI regulation across industries. With its broad territorial scope and applicability, this comprehensive legislation establishes stringent requirements for AI systems. This presentation is based on a forthcoming article in *NPJ Digital Medicine* co-authored with Mateo Aboy and Effy Vayena. It analyzes the AI Act's impact on digital medical products such as medical devices: How does the AI Act apply to AI/ML-enabled medical devices? How are they classified? What are the compliance requirements? How does it compare to the MDR? And, what are the obligations of 'providers' of these AI systems? After addressing these foundational questions, Timo Minssen will also discuss the AI Act's broader implications for the future of medical device innovation.

Biography:

Prof Timo Minssen is Professor of Law and the Founding Director of the Center for Advanced Studies in Bioscience Innovation Law (CeBIL) at the University of Copenhagen. He is also the PI of the NNF's Inter-CeBIL programme, as well as a Research Affiliate at the University of Cambridge's LML and at Harvard Law School's Petrie-Flom Centre for Health Law Policy, Biotechnology & Bioethics. His research, supervision, teaching & advisory practice concentrates on IPRs, Competition & Regulatory Law with a special focus on new technologies, big data & AI in the health & life sciences. Based on his academic and practical experience from law firms, courts & life science start-ups, Timo serves as an advisor and member of expert committees at the WHO, WIPO, EU Commission, various organizations, companies, national governments and law firms. He has published 7 books, as well as 220+ articles and book chapters, which have been featured in i.a. *The Economist, The Financial Times, El Mundo, Politico, WHO Bulletin, Times of India & Times Higher Education*, as well as in leading law journals and science magazines, such as *Science, NEJM Catalyst, JAMA, Harvard Business Review, Harvard Business Manager, Nature Biotechnology, Nature Genetics, Nature Electronics, Nature PJ Digital Medicine & The Lancet Digital Health*.

Presentation Title: From Code to Care: Regulating AI in Canadian Healthcare

Speaker:
Yuan Y. Stevens, Academic Associate, Centre of Genomics and Policy, McGill University, Canada

Abstract:

Artificial intelligence (AI) is revolutionizing healthcare, from enhancing medical imaging diagnostics to accelerating drug discovery and improving surgical precision. As AI's role in patient care expands, so does the need for comprehensive regulation. This talk explores Canada's multi-faceted approach to governing AI in healthcare, focusing on three key areas: medical device regulation, privacy and data protection laws, and the proposed *Artificial Intelligence and Data Act* (AIDA).

In this talk, we will examine how AI-based healthcare tools are evaluated under existing medical device frameworks, including pre-market assessment and post-market surveillance. The discussion will cover the interplay between federal and provincial privacy laws in safeguarding patient data. Finally, we will analyze AIDA's proposed risk-based approach to AI regulation and its potential impact on healthcare innovation. By examining these intersecting regulatory landscapes that govern the real-world testing and use of AI, this talk aims to provide key insights into the future of AI governance in Canadian healthcare.

Biography:

Yuan Stevens is a legal and policy advisor with expertise on technology, human rights, and AI governance. She brings years of international experience to her role as an Academic Associate at the Centre of Genomics and Policy at McGill University, having examined the impacts of technological developments on marginalized populations in Canada, the US and Europe.

Yuan obtained her Juris Doctor and B.C.L. from McGill University, winning numerous awards for her academic excellence and contributions to her community. She completed her Masters of Laws (LL.M), Concentration in Law and Technology at the University of Ottawa, where Yuan was awarded the CLTS Impact Award by the Centre for Law, Technology and Society for her thought leadership on cybersecurity and digital rights.

Yuan’s research addresses questions of data governance, privacy, and human rights, with a focus on the meaningful inclusion of equity-seeking populations in the design and rollout of (generative) AI systems. She has written for popular media outlets such *The Toronto Star* and *Ottawa Citizen* and has been quoted in news stories by *The Globe & Mail, The CBC* and *The New York Times*.

Presentation Title: Regulating AI/ML in U.S. Healthcare: Challenges, Opportunities, and FDA's Evolving Framework

Speaker:
Prof Sara Gerke
Associate Professor of Law and Richard W. & Marie L. Corman Scholar, College of Law, University of Illinois Urbana-Champaign, US

Abstract:

This presentation provides an overview of the regulation of artificial intelligence and machine learning (AI/ML) in healthcare in the United States, with a focus on the U.S. Food and Drug Administration's (FDA) evolving role in regulating these technologies. It begins by examining key AI/ML applications in healthcare, from diagnostics to personalized medicine, and how these innovations are reshaping the industry. The discussion then turns to the U.S. Federal Food, Drug, and Cosmetic Act, outlining the criteria under which a health AI/ML-based product qualifies as a medical device. Special attention is given to the unique challenges posed by AI/ML technologies, such as their iterative nature, adaptability, and the complexities of ensuring safety, efficacy, and transparency. The presentation will also cover new FDA initiatives aimed at addressing these issues, including recent regulatory developments, such as the option for manufacturers to submit a predetermined change control plan.

Biography:

Sara Gerke is an Associate Professor of Law and Richard W. & Marie L. Corman Scholar at the University of Illinois College of Law. Her current research focuses on the ethical and legal challenges of artificial intelligence and big data for health care and health law in the United States and Europe.

Professor Gerke is leading several research projects funded by the NIH and the European Union. She has over 60 publications in health law and bioethics, especially AI and digital health. Her work has appeared in leading law, medical, scientific, and bioethics journals, including JAMA, Science, and Nature Medicine.

Before joining Illinois, Professor Gerke was an Assistant Professor of Law at Penn State Dickinson Law and was promoted early to Associate Professor of Law in 2024. Previously, she served as a Research Fellow in Medicine, Artificial Intelligence, and Law at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, where she oversaw the day-to-day work of the Project on Precision Medicine, Artificial Intelligence, and the Law (PMAIL).

Presentation Title: Managing Failure: How Should We Track and Govern Problems Arising from Medical AI/ML devices?

Speaker:
Prof Boris Babic
Associate Professor, HKU Musketeers Foundation Institute of Data Science and Department of Philosophy
Associate Professor (by courtesy), Faculty of Law
The University of Hong Kong, Hong Kong, China

Co-authors:
Prof I. Glenn Cohen
James A. Attwood and Leslie Williams Professor of Law, Harvard Law School,
Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics
Harvard University, US
&
Prof Ariel Dora Stern
Associate Professor of Business Administration, Technology and Operations Management Unit, Harvard Business School
Harvard University, US

Abstract:

Historically, the FDA has regulated failures of medical devices using a system of recalls and adverse event reports. In this project, we suggest that neither of these tools are particularly effective at identifying and correcting problems with AI/ML devices. For recalls and reporting requirements to work well, problems have to be concrete, serious, unambiguous and rectifiable. AI/ML devices can fail in ways that are concerning but fail to satisfy any or all of these desiderata. We explain why this is the case, and consider several alternatives for AI/ML medical device safety regulation.

Biography:

Boris Babic is Associate Professor of Data Science, Philosophy and (by courtesy) Law at the University of Hong Kong. Previously, he was an assistant professor at the University of Toronto, and an assistant professor at INSEAD (in France and Singapore). He received his PhD in Philosophy and MS in Statistics from the University of Michigan, Ann Arbor, and he received his JD from Harvard Law School. He completed a postdoctoral scholarship at the California Institute of Technology (Caltech) and practiced intellectual property and entertainment law at Quinn Emanuel in Los Angeles. His primary research interests are in legal, ethical, and policy dimensions of artificial intelligence and machine learning, particularly in medical applications.

Presentation Title: A GCC Approach Towards Regulating the Lifecycle of Healthcare AI

Speaker:
Dr Barry Solaiman
Assistant Professor of Law, College of Law, Hamad Bin Khalifa University, Qatar, Doha

Abstract:

This talk addresses the regulation of artificial intelligence (AI) across its entire lifecycle in the healthcare sector. Exploring developments in Qatar, Saudi Arabia and the United Arab Emirates (UAE), this talk offers a holistic regulatory approach premised on an amalgam of governance structures in the three GCC countries. Beginning with the research phase, it highlights the urgent need for robust guidelines and certification processes to ensure that AI technologies are developed in compliance with ethical and safety standards. Qatar offers a prime example of this approach. Moving into the approval stage, the discussion explores how AI systems can be effectively regulated under existing medical device frameworks, emphasising the need for tailored regulations that consider the unique challenges posed by AI. Saudi Arabia exemplifies this approach. Finally, the talk delves into the deployment of AI in clinical practice, examining the gaps in current laws and the pressing need for a coherent and consistent regulatory framework that can adapt to the rapid advancements in AI technology. The UAE offers a nuanced framework in this regard. The talk argues that the existing legal structures are inadequate, often inconsistent, and fail to address the complexities of AI in healthcare, making the case for a comprehensive overhaul of regulatory approaches to ensure patient safety, efficacy, and ethical integrity throughout the AI lifecycle.

Biography:

Dr Barry Solaiman is the Associate Dean for Academic Affairs and an Assistant Professor specializing in Healthcare Law at HBKU Law. He is also an Adjunct Assistant Professor of Medical Ethics in Clinical Medicine at Weill Cornell Medicine – Qatar, where he serves as Co-Director of the Intersection of Law and Medicine Conference Series. He holds a PhD in Law from the University of Cambridge and is a Fellow of Harvard Medical School's Center for Bioethics. He was formerly Editor-in-Chief of both the Cambridge International Law Journal and Medicine and Law. He is co-editor of the Research Handbook on Health, AI and the Law, which is the leading book in the field. He has published in leading journals on the regulation of AI in healthcare and was Lead Principal Investigator for a grant at HBKU that created guidelines for the development of AI in healthcare research.

Presentation Title: Role of AI in Medical and Public Healthcare Policymaking

Speaker:
Prof Brian Wong
Assistant Professor, Department of Philosophy, The University of Hong Kong, Hong Kong, China

Abstract:

Medical ethics places significant emphasis upon four key pillars of considerations: beneficence - the duty to "do good", nonmaleficence - the duty to "do no harm", autonomy - respect for the patient's individual choices and right to self-determination, and justice - ensuring that patients do not receive differential access to healthcare and services in view of arbitrary and morally irrelevant factors. The rise of AI has presented new challenges and 'stressors' on each of these fronts, which require active acknowledge and consideration through drawing upon literature on algorithmic injustice, testimonial quieting and smothering (epistemic injustice), and the interactions between data control, ownership, usage, and the accountability and behaviours of medical professionals. This presentation delineates some of these moral risks, prior to advancing a range of broadly defined, big-picture complementary principles that can be adopted in refining and regulating the usage of AI. Whilst there will not be intricate discussion of the knitty-gritty or finer details of AI law, given both how nascent and rapidly morphing the field currently is, this presentation aims to provide a robust and enduring ethical framework that guides medical professionals, practitioners, and ethicists alike to reflect upon and update their ethical frameworks in embracing the 21st century and the many nascent technological advancements in this era. All actors residing in an automation/AI-influenced economy bear forward-looking responsibilities to see to the adoption of these standards.

Biography:

Prof Brian Wong is an Assistant Professor in Philosophy at the University of Hong Kong. His research examines the intersection of geopolitics, political and moral philosophy, and technology, with particular interests in the ethics and dynamics of authoritarian regimes and their foreign policies, responding to historical and colonial injustices, and the impact of automation on labour and human societies. Brian is a Fellow at the newly established Centre on Contemporary China and the World, at the University of Hong Kong. As the Chief Strategy Officer of the HK-ASEAN Foundation, he advises multi-national corporations, family offices, and leading think-tanks on geopolitical affairs and macro risks throughout Asia. Having co-founded and served as the inaugural Editor-in-Chief at the *Oxford Political Review*, a publication aspiring to bridge the theory-practice gap, Brian serves as a columnist at the Hong Kong Economic Journal. His writings on Chinese political economy, Asian geopolitics, and public philosophy have been featured in publications such as *TIME, Foreign Policy, Aeon, Financial Times, Diplomat, Fortune, The Hindu, South China Morning Post, Nikkei, Japan Times*, and *the US-Asia Law Institute*. He has also been interviewed by CNN, Al Jazeera, and CGTN for his views on Chinese foreign policy. A Rhodes Scholar (HKSAR, 2020), Brian holds a DPhil in Politics, an MPhil in Political Theory (Distinction), and an MA in Philosophy, Politics, and Economics from the University of Oxford.

Presentation Title: Medical AI Assistants vs. Medical AI Dictators

Speaker:
Prof Herman Cappelen
Chair Professor, Department of Philosophy
Director of AI & Humanity Lab and Co-director of ConceptLab
The University of Hong Kong, Hong Kong, China

Abstract:

In the evolving landscape of medicine, Artificial Intelligence (AI) presents both remarkable opportunities and profound challenges. On one hand, **Medical AI Assistants** provide valuable support: they offer expert advice, ensure that work is performed accurately, never tire, avoid common human errors, and help healthcare professionals enhance their performance. Human doctors remain in charge, but their work and decisions are significantly augmented by AI assistance.

On the other hand, we face the imminent rise of **Medical AI Dictators**. Soon, AI systems may diagnose patients and prescribe treatments that are too complex for humans to understand—perhaps drawing upon comprehensive models of our brains, detailed analyses of our body's chemical structures, and predictive accounts of our interactions with the environment over years to come. In effect, life-and-death decisions would be made by processes beyond human comprehension.

This talk focuses on Medical AI Dictators. I'll consider two attitudes we can have to them:

- **Happy Deference**: We might defer to these AI decisions much like we currently trust human medical experts, accepting that our cognitive limitations prevent us from grasping the AI's complexity. From this perspective, preferring human over artificial expertise could be seen as anthropocentric hubris.
- **Defiance**: Alternatively, we may argue that humans should rely on human-understandable expertise and should not base medical treatments on systems beyond our comprehension.

While defiance might initially seem irrational, I'll consider five compelling, albeit non-conclusive, arguments supporting it:

- **Normative Judgments**: Determining what constitutes an illness or acceptable treatment involves value-laden and moral judgments. Such normative decisions ought to be made by humans.
- **Empathy in Care**: Effective treatment often requires empathy—an understanding and sharing of patients' feelings—which AI inherently lacks.
- **Autonomy and Informed Consent**: For patients to be treated as autonomous agents, they must understand and give informed consent to their treatments. Without comprehension, patients are reduced to passive subjects.
- **Accountability**: In the event of errors or adverse outcomes, the lack of clear accountability in AI-driven decisions poses significant ethical and legal challenges. Accountability is essential for a well-functioning medical system.
- **Unchecked Power**: Those who own and control these advanced AI systems could gain unparalleled influence over individuals' lives, raising concerns about power concentration and the potential for misuse.

Biography:

Professor Cappelen is a Chair Professor of Philosophy at the University of Hong Kong. He is the Director of the AI & Humanity Lab at HKU, the Director of IDEAS (part of the Institute of Data Science at HKU), the Director of the MA programme in *AI, Ethics, and Society*, and the Coordinator of a new part of the Common Core devoted to artificial intelligence. Professor Cappelen is the author or co-author of eleven influential monographs and more than 50 highly cited papers. His research spans many areas of philosophy, with much of his recent work focusing on issues in the philosophy of AI. He has written about the linguistic and cognitive capacities of AI, existential risks from AI, and the possibility of explainable and interpretable AI. His first book on AI is titled *Making AI Intelligible: Philosophical Perspectives* (Oxford University Press, 2021).

Presentation Title: Ethical considerations for the trustworthy use of medical AI

Speaker: Tanya Brigden
Senior Policy Analyst, PHG Foundation, University of Cambridge, UK

Abstract:

It is anticipated that the use of artificial intelligence (AI) could transform healthcare. Both for patients who might benefit from more accurate and effective disease detection, diagnosis, and treatment, but also for clinicians who could use AI to support medical decision-making, provide real-time assistance and insights, and reduce time spent on administrative tasks.

At the same time, the integration of AI in healthcare raises a number of possible risks and concerns. How can we prevent AI from exacerbating healthcare biases and inequities? To what extent does the AI need to be transparent and explainable? For example, if a statistically superior model is less interpretable, would it be ethical to reject it? And what is the nature and level of human involvement that may be appropriate for the implementation of AI tools?

This presentation will highlight key ethical considerations relevant to healthcare professionals that use AI tools, and explore the soft and hard governance mechanisms that may be necessary for patients and clinicians to meaningfully place trust in these tools.

Biography:

Tanya is a Senior Policy Analyst (Biomedical Ethics) at the PHG Foundation, working on ethical and legal considerations arising from biomedical innovation and personalised healthcare. She contributes to a broad portfolio of PHG interests, and has developed expertise in a diverse range of topics including the use of genomic technologies (such as polygenic scores and genome editing), and artificial intelligence in healthcare.

Beyond her role at PHG Foundation, Tanya is the Ethicist member of the NHS Cambridgeshire and Peterborough Clinical Policies Forum, and is a member of the NHS Cambridgeshire and Peterborough System-wide Ethics Committee. Tanya has an MA in Medical Ethics and Law from Kings College London, a Graduate Diploma in Law, and a BA in Philosophy from Durham University

Presentation Title: The AI as expert: some epistemological and moral considerations

Speaker: Dr Pete Mills
Director, PHG Foundation, University of Cambridge, UK

Abstract:

Developments in AI offer benefits in medical practice that extend beyond those of labour-saving automation and computational prowess offered by 'unintelligent' machines. AI is increasingly incorporated into medical devices, constituted as medical devices and engaged as support for clinical decision making. It is empirically demonstrated that, on measures of clinical utility, AI can outperform humans in tasks conventionally requiring clinical judgement. How should we understand the contribution that AI can make? Looking through an epistemological lens in order to set aside anthropocentric bias I will consider the different possibilities of interacting with AI in clinical practice as a tool, as an expert team member and as factotum. I will then elaborate some moral implications of decisions to incorporate AI into clinical practice and the ongoing requirements that such decisions should place on those who are inclined to do so.

Biography:

Pete Mills is the Director of the PHG Foundation, an interdisciplinary health policy research organisation and linked charity of the University of Cambridge, with the mission 'to make science work for health'. Originally trained in philosophy, Pete has worked for nearly 25 years at the intersection of emerging science, ethics and public policy. Prior to joining the PHG Foundation in 2023, Pete was Associate Director at the Nuffield Council on Bioethics and before that he led the Secretariat of the Human Genetics Commission. He has also held senior policy positions at the UK Department of Health and the Human Fertilisation & Embryology Authority, and has served in representative and advisory roles on several national and international bodies dealing with genomics, bioethics and human rights. For his first degree, Pete read Philosophy, Politics and Economics at Trinity College, Oxford, and he has an MA and PhD in Philosophy from the University of Warwick.

Presentation Title: Emerging ethical challenges in medical AI: persuasion, manipulation and consent

Speaker: Prof Rachel Sterken
Associate Professor, Department of Philosophy
Co-director of ConceptLab
The University of Hong Kong, Hong Kong, China

Abstract:
This presentation will review new forms of AI manipulation which pose a risk to medical applications and how these may undermine trust and consent.

Biography:

Prof Rachel Sterken is Associate Professor of Philosophy, Chairperson of the Philosophy Department, and Associate Dean (Postgraduate) in the Faculty of Arts at HKU. Prior to joining HKU, she was Associate Professor at the University of Oslo.

Prof Sterken's main research interests are in philosophy of language and communication, conceptual ethics, social epistemology. philosophy and ethics of information/data, and philosophy of technology. Her work is published in leading philosophy journals such as *Philosopher's Imprint*, *Philosophical Studies*, and *Journal of Ethics and Social Philosophy*.

Prof Sterken has taught numerous courses across professional, BA, MA, and PhD levels; including ethics of AI, logic, critical thinking, core ethics, philosophy of language, philosophy of mind, metaphysics, and ethics of information.

WiFi

FREE **WiFi** service is provided in the conference venue. Connection to **Wi-Fi.HK via**. **HKU** is easy and no registration is required. Only 3 steps to connect:

1. Ensure that WiFi is turned ON;
2. Find the access point “Wi-Fi.HK via HKU”;
3. Open a browser and accept the Terms and Conditions.

For those with an account from an academic institution, access via the eduroam service is also available. Please log onto the eduroam access point, entering your full email address (e.g. onetwothree@abc.edu) and your email password for that account.

Detailed connection procedures for different operating systems can be found at:
http://www.its.hku.hk/documentation/guide/network/wifi/wifihk

About the Organisers

Organiser:

CMEL

THE UNIVERSITY OF HONG KONG
CENTRE FOR MEDICAL ETHICS AND LAW

The Centre for Medical Ethics and Law (CMEL) develops new ideas and solutions in response to the big ethical, legal and policy questions of medicine and health. CMEL is the first cross-faculty interdisciplinary institution of its kind in the region. It was founded in 2012 by the LKS Faculty of Medicine and Faculty of Law at The University of Hong Kong as a joint inheritor of their vibrant intellectual traditions dating back to 1887 and 1969 respectively.

Today, CMEL brings together bioethicists, academic lawyers, medical scientists, and other scholars to conduct cutting edge bioethical and legal research and contribute to policy development in flagship areas like digital health and emergent technologies, mental health and capacity, and population and global health.

Research, teaching and knowledge exchange—CMEL's core initiatives—aim to ensure that developments in biomedicine and public health will be underpinned by ethical and legal considerations.

Centre for Medical Ethics and Law, Faculty of Law, The University of Hong Kong

Address: Office 9.21, 9th Floor, Cheng Yu Tung Tower, Centennial Campus, The University of Hong Kong
Email: cmel@hku.hk
Tel: (852) 3917 1845
Fax: (852) 2549 8495
Website: https://cmel.hku.hk
Twitter: @HKUCMEL
LinkedIn: https://www.linkedin.com/company/hku-cmel/
Facebook: https://www.facebook.com/pg/CMELHKU
Instagram: https://www.instagram.com/hku_cmel/

Subscribe for updates & newsletters: https://bit.ly/3mCkVaZ

Supporting Organisations:

HONG KONG ACADEMY OF MEDICINE
香港醫學專科學院

HKU Med School of Clinical Medicine
Medical Ethics & Humanities Unit
香港大學醫學倫理及人文學部